Erratum: Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling (Molecular and Cellular Proteomics (2014) 13 (1429-1438) DOI: 10.1074/mcp.M113.033845);Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling

Molecular and Cellular Proteomics

Volumn 13, Issue 6, 2014, Pages 1429-1438

  Masuda, Mari ^a   Chen, Wei Yu ^b   Miyanaga, Akihiko ^a   Nakamura, Yuka ^a   Kawasaki, Kumiko ^c   Sakuma, Tomohiro ^c   Ono, Masaya ^a   Chen, Chi Long ^b   Honda, Kazufumi ^a   Yamada, Tesshi ^c  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Mitsui Knowledge Industry Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; SERINE; SORAFENIB; CARBANILAMIDE DERIVATIVE; MTOR PROTEIN, HUMAN; NICOTINAMIDE; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; EXON; FLUORESCENCE; GENE SEQUENCE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEOMICS; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84901919742     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.AAC119.001903     Document Type: Erratum

References (28)

1. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917
2. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., and Bruix, J. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390
3. Arao, T., Ueshima, K., Matsumoto, K., Nagai, T., Kimura, H., Hagiwara, S., Sakurai, T., Haji, S., Kanazawa, A., Hidaka, H., Iso, Y., Kubota, K., Shimada, M., Utsunomiya, T., Hirooka, M., Hiasa, Y., Toyoki, Y., Hakamada, K., Yasui, K., Kumada, T., Toyoda, H., Sato, S., Hisai, H., Kuzuya, T., Tsuchiya, K., Izumi, N., Arii, S., Nishio, K., and Kudo, M. (2013) FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 57, 1407-1415
4. Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T. S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W. Y., Pan, H., Burock, K., Zou, J., Voliotis, D., and Guan, Z. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 10, 25-34
5. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140
6. Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J. Y., Lathia, C., Schwartz, B., Taylor, I., Moscovici, M., and Saltz, L. B. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (Pubitemid 46630787)
7. Ueshima, K., Kudo, M., Takita, M., Nagai, T., Tatsumi, C., Ueda, T., Kitai, S., Ishikawa, E., Yada, N., Inoue, T., Hagiwara, S., Minami, Y., Chung, H., and Sakurai, T. (2011) Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig. Dis. 29, 321-325
8. Hagiwara, S., Kudo, M., Nagai, T., Inoue, T., Ueshima, K., Nishida, N., Watanabe, T., and Sakurai, T. (2012) Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br. J. Cancer 106, 1997-2003
9. Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., Munson, P. J., Petricoin, E., 3rd, Liotta, L. A., and Weinstein, J. N. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new highdensity reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U.S.A. 100, 14229-14234 (Pubitemid 37499219)
10. Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., Masrorpour, F., Shen, L., Liu, W., Duchemann, B., Tumula, P., Bhardwaj, V., Welsh, J., Weber, S., Glisson, B. S., Kalhor, N., Wistuba, I. I., Girard, L., Lippman, S. M., Mills, G. B., Coombes, K. R., Weinstein, J. N., Minna, J. D., and Heymach, J. V. (2012) Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2, 798-811
11. Spurrier, B., Ramalingam, S., and Nishizuka, S. (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat. Protoc. 3, 1796-1808
12. Bolstad, B. M., Irizarry, R. A., Astrand, M., and Speed, T. P. (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (Pubitemid 36181903)
13. Masuda, M., Maruyama, T., Ohta, T., Ito, A., Hayashi, T., Tsukasaki, K., Kamihira, S., Yamaoka, S., Hoshino, H., Yoshida, T., Watanabe, T., Stanbridge, E. J., and Murakami, Y. (2010) CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J. Biol. Chem. 285, 15511-15522
14. Li, H., and Durbin, R. (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760
15. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., and Genome Project Data Processing, S. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079
16. Wang, K., Li, M. Y., and Hakonarson, H. (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38(16):e164.
17. Chou, T. C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446
18. Anjum, R., and Blenis, J. (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9, 747-758
19. Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C., and Thomas, G. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 3112-3124 (Pubitemid 38452057)
20. Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N., and Blenis, J. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 282, 14056-14064 (Pubitemid 47100467)
21. Ascierto, P. A., Kirkwood, J. M., Grob, J. J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., and Mozzillo, N. (2012) The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85
22. Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., Battiston, C., Van Laarhoven, S., Fiel, M. I., Di Feo, A., Hoshida, Y., Yea, S., Toffanin, S., Ramos, A., Martignetti, J. A., Mazzaferro, V., Bruix, J., Waxman, S., Schwartz, M., Meyerson, M., Friedman, S. L., and Llovet, J. M. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972-1983
23. Zhou, L., Huang, Y., Li, J., and Wang, Z. (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med. Oncol. 27, 255-261
24. Zhu, A. X., Abrams, T. A., Miksad, R., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., Muzikansky, A., Clark, J. W., Kwak, E. L., Schrag, D., Jors, K. R., Fuchs, C. S., Iafrate, A. J., Borger, D. R., and Ryan, D. P. (2011) Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117, 5094-5102
25. Kudo, M. (2011) Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig. Dis. 29, 289-302
26. Wagner, E. F., and Nebreda, A. R. (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537-549
27. Uhlen, M., and Ponten, F. (2005) Antibody-based proteomics for human tissue profiling. Mol. Cell. Proteomics 4, 384-393 (Pubitemid 40590558)
28. Wulfkuhle, J. D., Edmiston, K. H., Liotta, L. A., and Petricoin, E. F., 3rd (2006) Technology insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat. Clin. Pract. Oncol. 3, 256-268